Filing Flows

Filing Flows › 8-K events › DataMeds AI

DataMeds AI: entry into a material definitive agreement

Form 8-K filed Oct 26, 2026 · items 1.01, 7.01

Mergers and acquisitionsDataMEDS AI Enters Into Amended and Restated LOI to License and Acquire IP that Enables Goal-Driven Prescription Drug Telehealth, Medical Drones and Healthcare Blockchain Technologies

What the filing says

As previously disclosed, DataMEDS AI, Inc. (formerly Wellgistics Health, Inc.) (the “Company”) entered into a Fully Binding Term Sheet, dated May 18, 2026 (the “Term Sheet”), and an Amended and Restated Letter of Intent, dated July 29, 2026 (the “First A&R LOI”), with EOS Technology Holdings, Inc. (“EOS”), Scilex Holdi

Read the filing on SEC EDGAR →

What usually followsAcross 23,525 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Every item ranked →

What this kind of filing means

Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.

DataMeds AI at a glance

Latest quarterQ2 2026
Revenue$1.8M
Revenue Y/Y-77%
Operating margin-412.7%
IndustryWholesale-Drugs, Proprietaries & Druggists' Sundries

DataMeds AI, Q2 2026: revenue $1.8M (-77% year over year), operating margin -412.7%. The chart follows the revenue to costs, profit and cash.

DataMeds AI: every quarter, Q/Q and Y/Y, holders and guidance →

DataMeds AI’s other material 8-Ks

Other recent mergers and acquisitions

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.